Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPS

Tango Therapeutics (NASDAQ:TNGX) issued its quarterly earnings data on Monday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02), Zacks reports. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.

Tango Therapeutics Stock Up 1.8%

NASDAQ TNGX opened at $1.12 on Monday. The company has a market cap of $121.08 million, a price-to-earnings ratio of -0.95 and a beta of 1.02. Tango Therapeutics has a 52 week low of $1.03 and a 52 week high of $12.02. The business has a 50 day moving average price of $1.51 and a 200-day moving average price of $2.66.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a research report on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $12.33.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.